How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages

When economist Chuck Manski was treated for advanced melanoma, the prescribed immunotherapy left him with a ruined thyroid and chronic physical discomfort. Despite the FDA-approved protocol demanding a full year of treatment, his doctors couldn't explain why that specific duration was necessary.

After researching medical journals, Manski decided to stop his treatment early. His personal choice aligns with a growing global trend where doctors in countries like India and Sweden are successfully using much lower doses of popular drugs like Opdivo and Keytruda.

The High Cost of Overdosing

The financial implications of these high dosages are staggering. One study estimated that using only the minimum necessary doses for 29 major cancer drugs could save the U.S. healthcare system approximately $31 billion in a single year.

However, there is little incentive for pharmaceutical giants to scale back. Merck’s Keytruda brought in $32 billion last year, while Bristol Myers Squibb earned $10 billion from Opdivo. Reducing doses would directly slash these massive profit margins.

Hospitals also benefit from the current system. Through federal programs, they often buy drugs at discounts and charge insurers more, with doctors receiving a percentage of the drug's price. "Pembrolizumab is the lifeblood of American hospitals," notes pharmacologist Mark Ratain.

Global Success vs. Local Resistance

In India, oncologists have found that using as little as one-twelfth of the recommended dosage of nivolumab still provided powerful results against cancer. While these findings are promising, many U.S. doctors view them as mere curiosities rather than actionable data.

Some American oncologists are taking matters into their own hands. Dr. Kathy Miller of Indiana University often starts breast cancer patients on lower doses than the label suggests, sometimes even advising patients to skip pills to bypass insurance restrictions tied to standard dosing.

A New Path for Patient Care

The FDA has recently launched Project Optimus, an initiative aimed at forcing drug companies to conduct more precise dosing studies before a drug hits the market. The goal is to move away from the 'more is better' philosophy that has dominated oncology for decades.

Advocates argue that for patients with advanced cancer, quality of life is just as important as survival. As Julie Gralow of ASCO states, the mission is to ensure treatments aren't "compromising quality of life with higher doses that are unnecessary."